Salidroside Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via AMPK-Dependent TXNIP/NLRP3 Pathway

Figure 1

Effects of salidroside (SAL) on body weight, postprandial blood glucose, and insulin sensitivity in high-fat diet (HFD) mice. Vehicle or SAL (100 mg·kg⁻¹·d⁻¹) was administered orally to regular diet (RD) or HFD mice for 8 weeks, and body weight (a), postprandial blood glucose (b), intraperitoneal glucose tolerance test (IPGTT) (c), intraperitoneal insulin tolerance test (IPITT) (d), fasting blood glucose (FBG) (e), fasting serum insulin (f), and the homeostasis model assessment-insulin resistance (HOMA-IR) index (g) were detected. AUC: area under curve. , versus RD mice treated with vehicle; , versus HFD mice treated with vehicle. Values are means ± s.e.m. ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)